a. Known history of hypersensitivity to dietary supplements. <br/ >b. Volunteers receiving any COVID-19 specific antiviral treatment. <br/ >c. Concurrent respiratory diseases such as COPD (chronic obstructive pulmonary disease), IPF and/or intermittent, persistent or more severe asthma requiring daily therapy or any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks (28 days) prior to COVID-19 diagnosis. <br/ >d. Malignancy within the past 3 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I. <br/ >e. Volunteers having systemic diseases like diabetes mellitus (Type I or Type II) and other debilitating metabolic diseases. <br/ >f. Pregnant or lactating women <br/ >g. Female subjects of childbearing potential not willing to use contraceptive methods <br/ >h. Male subjects not willing to use contraceptive methods <br/ >i. On-going treatment with herbals or any other immune boosting dietary supplements. <br/ >j. History of having received any investigational drug or participated in any other clinical trial which ended in the preceding three months or currently ongoing. <br/ >k. Patients with ARDS of Cardiac origin <br/ >

a. Known history of hypersensitivity to dietary supplements. <br/ >b. Volunteers receiving any COVID-19 specific antiviral treatment. <br/ >c. Concurrent respiratory diseases such as COPD (chronic obstructive pulmonary disease), IPF and/or intermittent, persistent or more severe asthma requiring daily therapy or any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks (28 days) prior to COVID-19 diagnosis. <br/ >d. Malignancy within the past 3 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I. <br/ >e. Volunteers having systemic diseases like diabetes mellitus (Type I or Type II) and other debilitating metabolic diseases. <br/ >f. Pregnant or lactating women <br/ >g. Female subjects of childbearing potential not willing to use contraceptive methods <br/ >h. Male subjects not willing to use contraceptive methods <br/ >i. On-going treatment with herbals or any other immune boosting dietary supplements. <br/ >j. History of having received any investigational drug or participated in any other clinical trial which ended in the preceding three months or currently ongoing. <br/ >k. Patients with ARDS of Cardiac origin <br/ >

N/A

N/A

a. Known history of hypersensitivity to dietary supplements. <br/ >b. Volunteers receiving any COVID-19 specific antiviral treatment. <br/ >c. Concurrent respiratory diseases such as COPD (chronic obstructive pulmonary disease), IPF and/or intermittent, persistent or more severe asthma requiring daily therapy or any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks (28 days) prior to COVID-19 diagnosis. <br/ >d. Malignancy within the past 3 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I. <br/ >e. Volunteers having systemic diseases like diabetes mellitus (Type I or Type II) and other debilitating metabolic diseases. <br/ >f. Pregnant or lactating women <br/ >g. Female subjects of childbearing potential not willing to use contraceptive methods <br/ >h. Male subjects not willing to use contraceptive methods <br/ >i. On-going treatment with herbals or any other immune boosting dietary supplements. <br/ >j. History of having received any investigational drug or participated in any other clinical trial which ended in the preceding three months or currently ongoing. <br/ >k. Patients with ARDS of Cardiac origin <br/ >

a. Known history of hypersensitivity to dietary supplements. <br/ >b. Volunteers receiving any COVID-19 specific antiviral treatment. <br/ >c. Concurrent respiratory diseases such as COPD (chronic obstructive pulmonary disease), IPF and/or intermittent, persistent or more severe asthma requiring daily therapy or any subjects that have had an asthma flare requiring corticosteroids in the 4 weeks (28 days) prior to COVID-19 diagnosis. <br/ >d. Malignancy within the past 3 years with the exception of in situ removal of basal cell carcinoma and cervical intraepithelial neoplasia grade I. <br/ >e. Volunteers having systemic diseases like diabetes mellitus (Type I or Type II) and other debilitating metabolic diseases. <br/ >f. Pregnant or lactating women <br/ >g. Female subjects of childbearing potential not willing to use contraceptive methods <br/ >h. Male subjects not willing to use contraceptive methods <br/ >i. On-going treatment with herbals or any other immune boosting dietary supplements. <br/ >j. History of having received any investigational drug or participated in any other clinical trial which ended in the preceding three months or currently ongoing. <br/ >k. Patients with ARDS of Cardiac origin <br/ >